# Veracyte (VCYT) — Earnings

VCYT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/vcyt/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.54 |
| EPS estimate | $0.43 |
| EPS surprise | +26.20% |
| Revenue surprise | +3.96% |
| Revenue | $150.3M |
| Revenue estimate | $144.6M |
| Reported | Jul 30, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1384101/000138410126000044/vcyt-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/c45babaa-645a-01df-c466-e719eccf5bcd.html) |

Veracyte reported Q2 2026 results on July 30, 2026. EPS was $0.54, beating the $0.43 estimate by 26.20%. Revenue of $150.3 million topped the $144.6 million consensus by 3.96%. Against Q2 2025, EPS rose about 23% from $0.44 and revenue rose about 15% from $130.2 million. Both are table highs.

The table shows a move from losses to profits. Veracyte posted a loss in every quarter from Q3 2021 through Q1 2024, the deepest at $0.41 per share in Q3 2023. It has been profitable in each of the nine quarters since. Annual results went from losses of $0.50 per share in 2022 and $1.03 in 2023 to earnings of $0.30 in 2024 and $1.79 in 2025. Revenue grew every year, from $297 million in 2022 to $517 million in 2025, a rise of about 74%. Over the last 20 quarters, Veracyte beat the EPS estimate 16 times. The most recent miss was Q4 2024, at 47.04% below.

Veracyte reported Q3 results between November 2 and November 9 in each of the past five years. That points to early November 2026 for the next report. It will show whether the year-over-year growth in EPS and revenue continues.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 30, 2026 | $0.43 | $0.54 | 26.20% | $144.6M | $150.3M |
| Q1 2026 | May 5, 2026 | $0.33 | $0.52 | 55.27% | $130.2M | $139.1M |
| Q4 2025 | Feb 25, 2026 | $0.41 | $0.53 | 29.52% | $135.4M | $140.6M |
| Q3 2025 | Nov 4, 2025 | $0.32 | $0.51 | 59.13% | $125.0M | $131.9M |
| Q2 2025 | Aug 6, 2025 | $0.28 | $0.44 | 57.65% | $121.0M | $130.2M |
| Q1 2025 | May 7, 2025 | $0.12 | $0.31 | 151.83% | $111.3M | $114.5M |
| Q4 2024 | Feb 24, 2025 | $0.11 | $0.06 | -47.04% | $116.7M | $118.6M |
| Q3 2024 | Nov 6, 2024 | $0.03 | $0.19 | 486.42% | $109.8M | $115.9M |
| Q2 2024 | Aug 6, 2024 | −$0.02 | $0.07 | 526.83% | $100.3M | $114.4M |
| Q1 2024 | May 7, 2024 | −$0.16 | −$0.02 | 87.42% | $93.4M | $96.8M |
| Q4 2023 | Feb 22, 2024 | −$0.10 | −$0.39 | -288.45% | $92.0M | $98.2M |
| Q3 2023 | Nov 7, 2023 | −$0.15 | −$0.41 | -179.86% | $84.4M | $90.1M |
| Q2 2023 | Aug 8, 2023 | −$0.15 | −$0.12 | 21.26% | $83.1M | $90.3M |
| Q1 2023 | May 4, 2023 | −$0.13 | −$0.11 | 18.22% | $75.8M | $82.4M |
| Q4 2022 | Feb 22, 2023 | −$0.15 | −$0.05 | 66.91% | $73.9M | $80.3M |
| Q3 2022 | Nov 2, 2022 | −$0.26 | −$0.12 | 53.54% | $66.4M | $75.6M |
| Q2 2022 | Aug 2, 2022 | −$0.22 | −$0.13 | 41.68% | $68.1M | $72.9M |
| Q1 2022 | May 3, 2022 | −$0.23 | −$0.20 | 13.72% | $61.9M | $67.8M |
| Q4 2021 | Feb 28, 2022 | −$0.16 | −$0.15 | 6.60% | $62.5M | $67.3M |
| Q3 2021 | Nov 9, 2021 | −$0.17 | −$0.20 | -17.65% | $54.0M | $60.4M |

## Frequently Asked Questions

### When did Veracyte (VCYT) last report earnings?

Veracyte last reported on Jul 30, 2026, covering fiscal Q2 2026.

### Did VCYT beat earnings estimates?

Yes. Veracyte reported EPS of $0.54 for Q2 2026 against a $0.43 estimate — a 26.20% beat.

### How much revenue did VCYT report last quarter?

Veracyte reported $150.3M in revenue for Q2 2026, against a consensus estimate of $144.6M.

## Similar Stocks

- [WST](https://www.lighthorse.io/tickers/wst) — West Pharmaceutical Services, Inc. Common Stock
- [GMED](https://www.lighthorse.io/tickers/gmed) — Globus Medical, Inc. Class A Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).